Trexquant Investment LP Has $14.40 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Trexquant Investment LP lessened its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 29.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 219,040 shares of the biotechnology company's stock after selling 91,662 shares during the quarter. Trexquant Investment LP owned 0.11% of BioMarin Pharmaceutical worth $14,397,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BMRN. Merit Financial Group LLC acquired a new position in BioMarin Pharmaceutical in the 4th quarter worth $317,000. Assenagon Asset Management S.A. lifted its holdings in shares of BioMarin Pharmaceutical by 461.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock valued at $40,205,000 after purchasing an additional 502,695 shares in the last quarter. Wedmont Private Capital acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $430,000. Swedbank AB grew its holdings in shares of BioMarin Pharmaceutical by 11.2% during the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after buying an additional 43,593 shares in the last quarter. Finally, Tidal Investments LLC grew its holdings in shares of BioMarin Pharmaceutical by 150.4% during the third quarter. Tidal Investments LLC now owns 30,467 shares of the biotechnology company's stock worth $2,142,000 after buying an additional 18,300 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BMRN. Scotiabank upped their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Wedbush reaffirmed an "outperform" rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Finally, Citigroup increased their price objective on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Remove Ads

BioMarin Pharmaceutical Price Performance

Shares of BMRN stock traded down $7.22 on Friday, hitting $60.26. 3,545,266 shares of the company's stock were exchanged, compared to its average volume of 1,855,047. The company has a 50 day moving average of $67.98 and a 200 day moving average of $67.31. The stock has a market cap of $11.50 billion, a P/E ratio of 27.39, a price-to-earnings-growth ratio of 0.61 and a beta of 0.30. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. BioMarin Pharmaceutical Inc. has a 12 month low of $60.02 and a 12 month high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, equities research analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the transaction, the chief accounting officer now owns 13,105 shares of the company's stock, valued at $896,119.90. This trade represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.